The risk factors for hepatic steatosis in patients with primary aldosteronism.


Journal

Endocrine journal
ISSN: 1348-4540
Titre abrégé: Endocr J
Pays: Japan
ID NLM: 9313485

Informations de publication

Date de publication:
29 Jun 2020
Historique:
pubmed: 28 3 2020
medline: 2 6 2021
entrez: 28 3 2020
Statut: ppublish

Résumé

Patients with primary aldosteronism (PA) are complicated by metabolic syndrome more frequently than those without PA. Hyperaldosteronism has been reported to be associated with a higher prevalence of non-alcoholic fatty liver disease (NAFLD). We aimed to clarify the risk factors for hepatic steatosis in the two subtypes of PA, comparing the status of hepatic steatosis in each of these subtypes. This was a retrospective observational study. We enrolled patients with an aldosterone producing adenoma (APA) (n = 33) or idiopathic hyperaldosteronism (IHA) (n = 56). Hepatic fat content was evaluated using the ratio of liver to spleen (L/S) X-ray attenuation on unenhanced computed tomography. L/S ratio <1.0 was utilized for assessing as hepatic steatosis. Age, sex distribution, visceral fat percentage (VF%), and visceral fat area (VFA) did not differ between patients with the two PA subtypes. The percentages of patients with L/S ratio <1.0 was not different between the two subtypes (APA: 21.2 % (7/33) vs. IHA: 19.6 % (11/56), p = 1.00). In both subtypes, the L/S ratio negatively correlated with VF% (APA: r = -0.66, p < 0.001; IHA: r = -0.66, p < 0.001) and with VFA (APA: r = -0.44, p < 0.01; IHA: r = -0.37, p < 0.01). The status of hepatic steatosis, evaluated using L/S ratio, did not differ between patients with APA or IHA. Hepatic steatosis was affected by the amount of visceral fat.

Identifiants

pubmed: 32213734
doi: 10.1507/endocrj.EJ19-0600
doi:

Substances chimiques

Aldosterone 4964P6T9RB

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

623-629

Auteurs

Yui Shibayama (Y)

Department of Diabetes and Endocrinology, Sapporo City General Hospital, 060-8604 Sapporo, Japan.
Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, 060-8648 Sapporo, Japan.

Norio Wada (N)

Department of Diabetes and Endocrinology, Sapporo City General Hospital, 060-8604 Sapporo, Japan.

Shuhei Baba (S)

Department of Diabetes and Endocrinology, Sapporo City General Hospital, 060-8604 Sapporo, Japan.

Shinji Obara (S)

Department of Diabetes and Endocrinology, Sapporo City General Hospital, 060-8604 Sapporo, Japan.

Hidetsugu Sakai (H)

Department of Radiation Technology, Sapporo City General Hospital, 060-8604 Sapporo, Japan.

Hiroaki Usubuchi (H)

Department of Diagnostic Radiology, Sapporo City General Hospital, 060-8604 Sapporo, Japan.

Satoshi Terae (S)

Department of Diagnostic Radiology, Sapporo City General Hospital, 060-8604 Sapporo, Japan.

Akinobu Nakamura (A)

Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, 060-8648 Sapporo, Japan.

Tatsuya Atsumi (T)

Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, 060-8648 Sapporo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH